Eduovisual
Musculoskeletal
Fibromyalgia: diagnosis and multimodal management
— Prevalence ~2–4% of US adults; female:male ratio ~2:1 (closer to 1:1 with newer criteria that de-emphasize tender points)
— Peak onset 30–55 years; commonly coexists with IBS, migraine, chronic pelvic pain, TMJ disorder, interstitial cystitis, depression, anxiety, and PTSD
— Altered central pain processing: ↑ glutamate/substance P in CSF, ↓ descending inhibition (serotonin/norepinephrine), abnormal functional MRI pain responses
— Not an autoimmune, inflammatory, or degenerative joint disease — labs and imaging are typically normal
— Patient with >3 months of "pain everywhere" — neck, back, shoulders, hips, alternating sides
— Multiple normal prior workups (CBC, CMP, ESR, TSH, ANA, RF)
— Wakes unrefreshed despite adequate sleep hours; complains of memory/concentration issues
— Symptoms triggered or worsened by physical/emotional stress, infection (e.g., post-viral), or trauma (MVC)
Board pearl: Fibromyalgia is a clinical diagnosis of inclusion, not exclusion — once you meet criteria, stop ordering serial labs/MRIs hunting for an alternative. Excessive workup reinforces illness behavior and is a recognized iatrogenic harm on Step 3 ambulatory stems.
Key distinction: FM ≠ chronic fatigue syndrome (ME/CFS); the dominant complaint in FM is pain, while in ME/CFS it is post-exertional malaise and profound fatigue, though significant overlap exists.
— Widespread pain — bilateral, above and below the waist, axial; described as aching, burning, "all my muscles hurt"
— Fatigue — disproportionate to activity, worsens through the day
— Sleep disturbance — non-restorative; alpha-wave intrusion into NREM on polysomnography
— Cognitive symptoms — word-finding difficulty, poor concentration, multitasking failure
— Headache (migraine or tension), IBS-pattern abdominal pain, dysmenorrhea, paresthesias without dermatomal pattern, dizziness, dry eyes/mouth, Raynaud-like cold sensitivity
— Sensitivity to light, sound, odors, weather changes — a clue to central sensitization
— Duration (must be ≥3 months for diagnosis)
— Pain map: have patient mark a body diagram — diffuse pattern supports FM
— Triggers: infection (EBV, Lyme post-treatment), MVC/whiplash, surgery, childbirth, psychosocial stressors, ICU stay
— Sleep hygiene, screen for obstructive sleep apnea (snoring, witnessed apnea, BMI, neck circumference) — easily missed and treatable mimic
— Mood: PHQ-9, GAD-7; ACEs (adverse childhood experiences) increase risk
— Functional status: work, exercise tolerance, ADLs, caregiving burden
— Substance use: opioids, cannabis, alcohol for sleep — all worsen FM long-term
Step 3 management: When a patient presents with diffuse pain plus fatigue, always screen for depression, sleep apnea, and hypothyroidism before anchoring on FM — these are reversible contributors and missing them is a common stem trap.
Board pearl: A history of childhood trauma, PTSD, or comorbid mood disorder is present in a large proportion of FM patients and should prompt early integrated behavioral health referral, not deferred care.
— Diffuse soft-tissue tenderness to light/moderate palpation — trapezius, suboccipital, supraspinatus, lateral epicondyle, gluteal, greater trochanter, medial knee fat pad
— No joint swelling, warmth, erythema, or effusion — if present, reconsider inflammatory arthritis
— Full passive ROM preserved; strength grossly intact though effort-limited by pain
— No muscle atrophy, fasciculations, or true weakness
— Sensory complaints diffuse and non-dermatomal; reflexes symmetric and normal; no upper motor neuron signs
— Romberg negative; gait normal unless deconditioned
— Thyroid: no goiter or nodule
— Lymph nodes: no lymphadenopathy
— Abdomen: may have diffuse tenderness without peritoneal signs (functional GI overlap)
— Widespread Pain Index (WPI) 0–19 and Symptom Severity Scale (SSS) 0–12 (2016 ACR criteria)
— Fibromyalgia Impact Questionnaire-Revised (FIQR) for tracking response
— 6-minute walk or sit-to-stand for baseline deconditioning
Key distinction: Tenderness everywhere (FM) vs discrete trigger points with referred pain and taut bands (myofascial pain syndrome) vs joint-line tenderness with effusion (true arthritis) — palpation pattern alone reorients your differential.
Board pearl: Any objective neurologic deficit, joint swelling, or systemic sign mandates a workup beyond FM — these are not part of the syndrome.
— CBC — anemia, leukopenia (SLE), macrocytosis (B12 deficiency, hypothyroidism, alcohol)
— CMP — calcium (hyperPTH), glucose, renal/hepatic function
— TSH — hypothyroidism is the classic FM mimic
— ESR and/or CRP — should be normal in FM; elevation prompts PMR/inflammatory arthritis workup
— 25-OH vitamin D — deficiency contributes to musculoskeletal pain; replete if <30 ng/mL
— CK — rule out inflammatory myopathy if proximal weakness present
— Ferritin/iron studies if restless legs or fatigue prominent
— ANA, RF, anti-CCP — only if joint swelling, rash, sicca, or other connective tissue features; a positive ANA in low titer occurs in 5–15% of healthy people and can mislead
— Lyme serology — only in endemic exposure with compatible history
— HIV, hepatitis C — if risk factors or fatigue prominent
— SPEP in older patients with bone pain (rule out myeloma)
— Polysomnography if OSA screen positive (STOP-BANG ≥3, witnessed apneas)
CCS pearl: On a CCS-style case, order CBC, CMP, TSH, ESR, CRP, CK, vitamin D once at intake, then advance the clock to discuss diagnosis and initiate management — repeating labs without new findings will cost you points.
Board pearl: Normal ESR/CRP in a patient with diffuse pain >3 months strongly supports FM over polymyalgia rheumatica or inflammatory arthritis.
— Widespread Pain Index (WPI) ≥7 AND Symptom Severity Scale (SSS) ≥5, OR WPI 4–6 AND SSS ≥9
— Generalized pain in ≥4 of 5 regions (left/right upper, left/right lower, axial); jaw, chest, abdomen excluded from region count
— Symptoms present at similar level for ≥3 months
— A diagnosis of FM is valid irrespective of other diagnoses — does not exclude clinically important other illness (an important change from earlier criteria)
— Name it explicitly — "You have fibromyalgia, a real, well-defined condition involving altered pain processing"
— Validate symptoms; explain central sensitization in plain language
— Set expectation: management, not cure; goal is improved function and quality of life
— Provide patient-education resources (e.g., ACR patient handouts, FibroGuide)
Step 3 management: Once criteria are met, stop the diagnostic odyssey. Continued specialist hopping and repeat imaging are markers of poor outcome — the correct next step is to initiate a multimodal treatment plan.
Key distinction: ACR 2016 criteria removed the tender-point exam — diagnosis is now based on symptom checklists, making it a history-driven diagnosis.
— Step 1 (all patients): Patient education, validation, sleep hygiene, graded aerobic exercise, and treatment of comorbid mood/sleep disorders
— Step 2 (inadequate response): Add cognitive behavioral therapy (CBT) ± targeted pharmacotherapy (duloxetine, milnacipran, pregabalin, low-dose amitriptyline)
— Step 3 (severe/refractory): Multidisciplinary pain program, combination pharmacotherapy, rheumatology/pain medicine consult
— Pain + depression → duloxetine (SNRI)
— Pain + poor sleep → low-dose amitriptyline at bedtime or cyclobenzaprine
— Pain + anxiety + sleep + neuropathic features → pregabalin at bedtime
— Pain + fatigue without depression → milnacipran (more NE activity, may be activating)
— Do not prescribe chronic opioids — no evidence of benefit, worsens central sensitization, opioid-induced hyperalgesia, addiction risk
— Avoid chronic NSAIDs and glucocorticoids — no inflammation to treat; GI/renal/CV harm
— Avoid benzodiazepines for sleep — tolerance, fall risk, cognitive worsening
— Avoid medical cannabis as first-line — evidence weak; reserve for refractory cases per shared decision-making
Board pearl: The single most evidence-based intervention for FM is graded aerobic exercise — pool-based or land — even when the patient says "exercise makes the pain worse." Start very low intensity and titrate by 10% weekly.
Step 3 management: When asked "next best step" in a newly diagnosed FM patient, choose exercise + education + CBT before pharmacotherapy unless severe pain/sleep disruption prevents engagement.
— Dose: start 30 mg daily × 1 week → 60 mg daily; max 120 mg (limited additional benefit above 60)
— Best for: FM + depression, FM + diabetic neuropathy, FM + chronic low back pain
— AEs: nausea (transient), dry mouth, somnolence, hypertension, sexual dysfunction, hyponatremia (elderly)
— Cautions: avoid in uncontrolled narrow-angle glaucoma; taper to stop (discontinuation syndrome); avoid with MAOIs; check BP at follow-ups
— Dose: 12.5 mg → titrate to 50 mg BID; max 200 mg/day
— More NE-selective → can improve fatigue and cognition; avoid if anxiety predominates
— AEs: nausea, hypertension, tachycardia, urinary hesitancy
— Dose: start 75 mg qHS, titrate over 1–2 weeks to 150–225 mg BID; max 450 mg/day
— Best for: pain + sleep disturbance + neuropathic features + anxiety
— AEs: sedation, dizziness, weight gain, peripheral edema, cognitive fog; Schedule V (misuse potential)
— Dose: 10–25 mg qHS, 2 h before sleep; rarely >50 mg
— Best for: poor sleep + pain; helpful in migraine/IBS overlap
— AEs: anticholinergic (dry mouth, constipation, urinary retention), orthostasis, weight gain, QT prolongation
— Avoid in elderly (Beers), narrow-angle glaucoma, recent MI, BPH
Board pearl: Tramadol has modest evidence but is not first-line due to seizure risk, serotonin syndrome with SNRIs, and dependence — reserve and avoid combining with duloxetine.
Key distinction: SSRIs (fluoxetine, sertraline) treat comorbid depression but have weaker effect on FM pain than SNRIs because they lack norepinephrine reuptake inhibition needed for descending pain modulation.
— Modality: walking, stationary cycling, aquatic exercise (warm-water pool — excellent for severe pain/deconditioning)
— Dose: start 5–10 min at low intensity 2–3×/week, increase by ~10% weekly to goal 30 min moderate intensity, 3–5×/week
— Counsel patient about expected transient pain flare in first 2–4 weeks — adherence often fails here; preempt
— 8–12 sessions; targets pain catastrophizing, sleep, coping, pacing, activity scheduling
— Effective in person or via validated digital programs (telehealth-friendly — Step 3 ambulatory favorite)
— Tai chi (multiple RCTs show benefit comparable to aerobic exercise), yoga, mindfulness-based stress reduction, qigong
— Strict sleep hygiene; consistent wake time; limit alcohol/caffeine; treat OSA with CPAP; restless legs with iron repletion (ferritin goal >75–100) and dopamine agonists if needed
— Pacing ("activity envelope"), energy budgeting, flare-management plan
— Acupuncture, hydrotherapy, balneotherapy, low-dose naltrexone (off-label, emerging), TENS
— Chiropractic high-velocity manipulation, prolonged bed rest, deactivation, chronic opioid escalation, repeated MRIs, injection chasing
— Encourage work continuation with accommodations (ergonomics, flexible hours) — work is protective; full disability worsens outcomes
— Avoid premature disability certification; engage occupational medicine when needed
CCS pearl: A high-yield multimodal CCS order set: "Patient education on fibromyalgia," "Refer to physical therapy for graded aerobic exercise program," "Refer to behavioral health for CBT," "Sleep hygiene counseling," plus a targeted first-line medication — all at the initial visit.
Board pearl: Combining exercise + CBT + an SNRI outperforms any single modality; FM is the prototypical "multimodal therapy wins" Step 3 topic.
— FM can present de novo or be carried into older age; new diffuse pain in elderly should first prompt PMR, malignancy, vitamin D deficiency, osteoporotic fracture, statin myopathy workup before settling on FM
— Beers criteria flags:
– Amitriptyline and other TCAs — strong anticholinergic load, falls, confusion → avoid
– Cyclobenzaprine — similar concerns, avoid chronic use
– Benzodiazepines, zolpidem — falls, fractures, delirium → avoid
— Preferred agents: duloxetine (monitor BP, hyponatremia, falls), low-dose gabapentin (sedation, edema)
— Exercise is still first-line — adapt with PT-supervised tai chi, aquatic therapy, chair-based programs
— Pregabalin and gabapentin are renally cleared — must dose-adjust:
– Pregabalin: CrCl 30–60 → 50% dose; CrCl 15–30 → ~25%; HD → supplemental dose after dialysis
– Gabapentin: similar tiered adjustments
— Duloxetine: avoid if CrCl <30 mL/min (accumulation of metabolites)
— Milnacipran: dose reduce if CrCl 5–29; avoid if ESRD
— Duloxetine: contraindicated in chronic liver disease, cirrhosis, and chronic heavy alcohol use (hepatotoxicity risk)
— Milnacipran: caution in severe hepatic impairment
— Acetaminophen for breakthrough pain: cap at 2 g/day in liver disease (not 4 g)
— Pregabalin/gabapentin: not hepatically metabolized — safer choices
— SNRI + tramadol/triptans → serotonin syndrome
— TCA + QT-prolonging agents (ondansetron, fluoroquinolones, methadone) → torsades risk — check ECG
— Multiple sedating agents (gabapentinoid + opioid + benzo) → respiratory depression, FDA boxed warning
Step 3 management: In an elderly FM patient with CKD stage 4, the best first-line med is low-dose duloxetine (if CrCl ≥30) or renally-dosed gabapentin at bedtime, paired with PT-supervised aquatic exercise — not amitriptyline.
Board pearl: Always reconcile medications and screen for falls at every FM visit in patients ≥65 — sedating regimens are the leading iatrogenic harm.
— FM symptoms often worsen in pregnancy and postpartum (sleep deprivation, hormonal shifts, mechanical load)
— Preferred approach: non-pharmacologic — prenatal yoga, walking, aquatic exercise, CBT, sleep optimization
— Pharmacologic options (only if needed, lowest effective dose, shared decision-making):
– Acetaminophen for breakthrough pain (preferred analgesic)
– Amitriptyline has the most pregnancy data among FM drugs but neonatal withdrawal possible near term
– Duloxetine: limited data; possible neonatal adaptation syndrome; weigh risk/benefit
– Pregabalin/gabapentin: emerging signal for major malformations with pregabalin; avoid if possible
– Avoid NSAIDs after 20 weeks (oligohydramnios, premature ductal closure)
– Avoid chronic opioids — neonatal abstinence syndrome
— Postpartum: screen aggressively for postpartum depression, support breastfeeding while continuing exercise
— Amitriptyline, duloxetine, sertraline (for comorbid depression) are generally compatible with breastfeeding
— Pregabalin/gabapentin: small amounts in breast milk; monitor infant for sedation
— Diagnosis based on modified criteria; CBT and aerobic exercise are first-line and highly effective
— School accommodations (504 plan), sleep schedule regularization, avoid opioids and chronic NSAIDs
— Family-based therapy when parental reinforcement of illness behavior is present
— "Concomitant FM" — present in ~20–30% of RA/SLE patients
— Distinguish persistent FM-driven pain from active inflammation — do not escalate biologics for non-inflammatory pain
— Treat both: optimize DMARDs and add FM-directed multimodal therapy
Key distinction: In adolescent FM, CBT + exercise has stronger evidence than any medication — pharmacotherapy is adjunctive, not primary.
Board pearl: A lupus patient with controlled serologies/inflammation but persistent diffuse pain and fatigue likely has superimposed fibromyalgia — recognize this rather than over-immunosuppress.
— Functional decline and disability — loss of work, social withdrawal, deconditioning spiral
— Mood disorders — major depression (lifetime ~60%), generalized anxiety, suicidality (elevated risk — screen)
— Sleep disorders — chronic insomnia, secondary obstructive sleep apnea worsening
— Weight gain and metabolic syndrome — inactivity plus sedating medications
— Chronic opioid use disorder when inappropriately prescribed
— Diagnostic odyssey harms: repeated imaging with incidentalomas leading to unnecessary procedures; gadolinium exposures; cumulative radiation
— Procedure cascade: trigger-point injections, repeated spinal injections, surgery for incidental MRI findings — poor outcomes when underlying pain is central
— Polypharmacy: sedation, falls, cognitive impairment, anticholinergic burden
— Opioid-induced hyperalgesia: paradoxically worsening pain with escalating doses
— Benzodiazepine dependence when used for sleep
— Duloxetine: hepatotoxicity, hypertension, hyponatremia (SIADH), bleeding risk with NSAIDs/anticoagulants, sexual dysfunction, suicidal ideation in young adults (boxed warning)
— Pregabalin/gabapentin: edema, weight gain, sedation, misuse and respiratory depression with opioids (boxed warning), withdrawal seizures if abruptly stopped
— Amitriptyline: cardiac conduction (QT), overdose lethality (narrow therapeutic index), anticholinergic delirium
— High utilization: frequent ED visits for pain flares, repeated specialist referrals; total annual cost ~3× general population
— Disability claims and litigation when post-traumatic FM is involved
— Caregiver burden, school absenteeism, family conflict around legitimacy of symptoms
Step 3 management: When a FM patient presents to ED with a pain flare, the correct disposition is outpatient optimization — not admission, opioids, or repeat imaging. Provide non-opioid analgesia, reinforce coping plan, and ensure same-week PCP follow-up.
Board pearl: Suicide risk in FM is 2–10× the general population — depression screening with PHQ-9 and suicidality assessment is standard of care at every visit.
— Rheumatology referral — diagnostic uncertainty, suspicion of overlap with inflammatory disease (positive ANA with clinical features, joint swelling, abnormal inflammatory markers)
— Pain medicine/multidisciplinary pain program — refractory pain despite optimized first-line therapy at 3–6 months, complex polypharmacy, opioid de-prescribing needed
— Behavioral health/psychiatry — moderate-severe depression, anxiety, PTSD, suicidality, substance use disorder
— Sleep medicine — suspected OSA, refractory insomnia, restless legs
— Physical therapy — every patient benefits; refer at diagnosis
— Occupational therapy and vocational rehab — work accommodations, ergonomic assessment
— Active suicidality or psychiatric emergency → ED/psych admission
— Severe medication adverse event — serotonin syndrome (SNRI + tramadol/triptan), TCA overdose, gabapentinoid + opioid respiratory depression
— Severe substance use disorder requiring detox
— Red-flag findings emerging — new focal neurologic deficit, weight loss, fevers — admit/expedite workup for missed diagnosis (malignancy, myositis, neurologic disease)
— New systemic features (fever, night sweats, weight loss)
— Focal pain pattern emerging from diffuse pain
— Objective weakness, sensory level, bowel/bladder dysfunction
— Elevated ESR/CRP on repeat
— New rash, oral ulcers, sicca, Raynaud
— Establish a primary care medical home as the quarterback
— Avoid fragmented care across multiple specialists ordering redundant tests
— Use shared electronic care plans and medication reconciliation
CCS pearl: On a CCS case, the appropriate consultations at diagnosis are PT, behavioral health/CBT, and rheumatology only if diagnostic uncertainty — not "pain clinic" reflexively, and never "neurosurgery" or "orthopedics" for non-focal pain.
Step 3 management: Inpatient admission for "fibromyalgia flare" is almost always the wrong answer — choose outpatient optimization and rapid follow-up instead.
— Age >50, bilateral shoulder/hip-girdle pain and stiffness, morning stiffness >45 min, ESR/CRP markedly elevated, dramatic response to prednisone 15–20 mg/day
— Distinguishes from FM by age, inflammatory markers, glucocorticoid response
— Symmetric small-joint synovitis (MCP, PIP, wrist), morning stiffness >1 h, RF/anti-CCP positive, joint erosions on imaging
— FM lacks synovitis, normal acute-phase reactants
— Malar rash, photosensitivity, oral ulcers, serositis, cytopenias, ANA + dsDNA/Smith antibodies, renal involvement
— Note: FM can be comorbid with SLE — confusing on stems
— Inflammatory back pain (improves with activity, worse at rest, night), HLA-B27, sacroiliitis on MRI, enthesitis, psoriasis/IBD/uveitis
— Proximal muscle weakness (objective), elevated CK, aldolase; rash in DM (heliotrope, Gottron)
— FM has pain without weakness or elevated CK
— Regional, not widespread; discrete trigger points with palpable taut bands and referred pain
— Responds to trigger-point injection, dry needling
— Joint-line pain, crepitus, bony enlargement (Heberden/Bouchard nodes), activity-related, radiographic joint-space narrowing
— Joint hypermobility (Beighton score ≥5), subluxations, dysautonomia overlap; often coexists with FM
— Proximal myalgia, ± CK elevation; resolves with statin withdrawal — always review med list
Key distinction: Inflammatory mimics (PMR, RA, SLE, myositis, spondyloarthritis) have objective findings — elevated ESR/CRP, synovitis, weakness, or positive autoantibodies — that FM lacks.
Board pearl: A patient over 50 with "fibromyalgia symptoms" and ESR >50 has PMR until proven otherwise — start prednisone and watch the dramatic response, then consider GCA evaluation.
— Fatigue, myalgia, weight gain, cold intolerance, constipation, bradycardia, dry skin; elevated TSH — order at every diffuse pain workup
— Diffuse bone and muscle pain, proximal weakness, elevated alk phos, low 25-OH vitamin D; replete and reassess
— Fatigue, unrefreshing sleep, cognitive symptoms — overlaps heavily with FM; STOP-BANG screen and polysomnography; CPAP can dramatically improve "FM" symptoms
— Dominant feature is post-exertional malaise lasting >24 h after minor exertion; pain less prominent than in FM
— Anhedonia, neurovegetative symptoms predominate; somatic symptom disorder shows excessive thoughts/behaviors disproportionate to symptoms
— Hyperparathyroidism (hypercalcemia, bone pain), Addison disease (fatigue, hyperpigmentation, hyponatremia), Cushing (weakness, central adiposity, striae)
— Hepatitis C (fatigue, arthralgia), HIV (diffuse symptoms, lymphadenopathy), Lyme (endemic exposure, EM rash, arthritis), post-acute COVID/long COVID (overlapping picture)
— Multiple myeloma (bone pain, anemia, renal injury, hypercalcemia — SPEP/UPEP in older patients), occult malignancy with paraneoplastic features, unexplained weight loss/B-symptoms
— Multiple sclerosis (focal neuro signs, optic neuritis), small-fiber neuropathy (burning distal pain — skin biopsy), peripheral neuropathy (diabetic, B12 deficiency)
— Statins, aromatase inhibitors, bisphosphonates, fluoroquinolones, interferons — review timeline
— Chronic alcohol use, opioid-induced hyperalgesia, stimulant withdrawal
Step 3 management: Whenever a stem includes weight loss, fever, lymphadenopathy, anemia, or elevated inflammatory markers, abandon the FM diagnosis path and pursue the systemic workup — these features are not part of FM.
Board pearl: Small-fiber neuropathy is increasingly recognized in patients labeled as FM (up to 30–50% by skin biopsy in some series); consider in patients with prominent burning, distal, length-dependent pain.
— Improve function, sleep, mood, and quality of life — not pain elimination
— Maintain employment, social engagement, and independence
— Prevent iatrogenic harm (polypharmacy, opioid use, deconditioning)
— Daily aerobic activity (target 150 min/week moderate intensity)
— Sleep schedule: consistent bed/wake times, no screens 30 min pre-sleep, limit caffeine after noon, no alcohol within 3 h of sleep
— Pacing: identify "activity envelope," avoid boom-bust cycles
— Flare plan: gentle stretching, hot bath, breathing exercises, continue baseline exercise at reduced intensity, schedule visit if >2 weeks
— Stress management: mindfulness, journaling, support group
— Reassess at 3 months; discontinue if no meaningful response (≥30% pain reduction or functional improvement)
— Annual deprescribing review — Beers/STOPP criteria in elderly
— Taper opioids and benzodiazepines if previously prescribed — use validated tapering protocols, behavioral support
— Cardiovascular risk reduction — patients with FM have higher CV risk via inactivity; calculate ASCVD score, address BP, lipids, smoking, diabetes screening
— Cancer screening per USPSTF (often deferred amid symptom focus — explicitly schedule)
— Immunizations up to date (annual flu, COVID, pneumococcal/zoster age-appropriate)
— Bone health — vitamin D, calcium, DEXA per guidelines; especially if chronic glucocorticoid exposure from comorbidity
— Weight management — exercise + nutrition counseling
— Dental and eye care — often neglected; SSRI/TCA dry mouth increases caries
— Regular PHQ-9/GAD-7; maintain CBT booster sessions or peer support
— Address adverse childhood experiences with trauma-informed care
Step 3 management: At every annual visit, perform medication reconciliation, depression screening, exercise review, sleep assessment, and preventive care updates — the FM visit is also a preventive visit.
Board pearl: Patients with FM still need routine USPSTF screening (mammography, colonoscopy, lipid panel, A1c, etc.) — symptom burden should not eclipse standard preventive care.
— Initial diagnosis: follow up at 2–4 weeks to reinforce education, troubleshoot exercise plan, titrate medication
— Titration phase (first 3 months): every 4–6 weeks
— Stable patient: every 3–6 months
— Annual comprehensive review: medications, function, comorbidities, preventive care
— Duloxetine: BP at each visit, LFTs at baseline and if symptoms, sodium in elderly, sexual function, suicidality (especially first 4 weeks)
— Pregabalin/gabapentin: weight, peripheral edema, sedation, mood, signs of misuse
— Amitriptyline: baseline ECG if age >50 or cardiac risk; anticholinergic burden, weight, falls
— Exercise: functional measures — 6-minute walk distance, sit-to-stand, self-reported activity minutes
— Outcome scales: repeat FIQR, PHQ-9, GAD-7, PROMIS pain interference every 3 months
— PT-supervised graded exercise program for 8–12 weeks
— Transition to independent community-based exercise (gym, pool, walking group, tai chi class)
— OT for ergonomics, energy conservation, adaptive strategies
— Validate experience; review progress on functional goals, not pain scores alone
— Reinforce exercise as "medicine," not optional
— Sleep, mood, stressors, substance use
— Address relationship/family dynamics around illness behavior
— ≥30% improvement in pain or function on validated scales
— Increased activity tolerance, return to work/school, reduced healthcare utilization
— No improvement after 6–12 months of adequate multimodal therapy → re-screen for missed mimics (OSA, hypothyroidism, small-fiber neuropathy, depression, occult inflammatory disease)
CCS pearl: Schedule the 2-week follow-up at the initial diagnostic visit — early reinforcement of the management plan and adherence check is high-yield and improves outcomes.
Board pearl: Track function and FIQR, not just pain — a stable pain score with improved work attendance and exercise tolerance is a treatment success.
— FM patients frequently report being dismissed; explicit validation is both an ethical duty (respect for persons) and a therapeutic intervention
— Avoid language that implies symptoms are "in your head" — frame as neurobiological
— Prescribing off-label (amitriptyline, cyclobenzaprine, gabapentin) — disclose off-label status, evidence base, and alternatives
— Pregabalin and gabapentinoid + opioid: FDA boxed warning for respiratory depression; document risk-benefit discussion if co-prescribing is unavoidable
— Duloxetine in young adults <25: discuss boxed warning for suicidality
— Chronic opioids are not recommended for FM; if inherited from prior prescriber, develop a shared, patient-centered taper
— Check PDMP at every controlled-substance prescription
— Naloxone co-prescription if any opioid + gabapentinoid or benzodiazepine
— Balance accurate disability documentation with the evidence that full work cessation worsens FM outcomes
— Favor accommodations and partial duty over total disability; engage occupational medicine
— Avoid filling out forms that overstate impairment to qualify for benefits — fraud risk and patient harm
— Suspected elder abuse, child abuse (consider when adolescent FM emerges in setting of family dysfunction), and intimate partner violence — screen routinely
— Patients with FM are often on multiple sedating medications; at hospital discharge or care transitions, perform formal medication reconciliation to prevent duplicative SNRIs, additive sedation, or inadvertent opioid escalation
— Communicate FM diagnosis and active medications to all subspecialists to prevent redundant workup
— FM is under-diagnosed in men and in minority populations; ensure equitable application of criteria
— Address access barriers to CBT, PT, and exercise programs (telehealth, community resources, Medicaid coverage advocacy)
— Record functional goals, shared decisions, taper plans, and risk-benefit conversations — protective medico-legally and clinically useful
Step 3 management: When a new patient presents on chronic high-dose opioids for FM from another clinician, the ethical and evidence-based next step is not abrupt discontinuation but a structured taper with behavioral support, naloxone, and close follow-up.
Board pearl: Validation + non-abandonment is itself a therapeutic intervention with measurable outcome benefit in chronic pain conditions.
— IBS, migraine, tension headache, TMJ disorder, interstitial cystitis/painful bladder syndrome, chronic pelvic pain, vulvodynia, restless legs syndrome, ME/CFS, MCS, POTS
Board pearl: When in doubt on a Step 3 FM stem, the answer is almost always "exercise + CBT + duloxetine (or pregabalin)" with reassurance and a 4-week follow-up — not more imaging, not opioids, not admission.
— 35-year-old woman, 6 months diffuse pain, fatigue, poor sleep, normal CBC/CMP/TSH/ESR/CRP, exam shows diffuse tenderness only → Diagnosis: fibromyalgia. Next step: education + graded aerobic exercise + CBT (not MRI, not ANA).
— FM patient with comorbid major depression → duloxetine
— FM patient with prominent insomnia → low-dose amitriptyline (or pregabalin)
— FM patient already on tramadol who you're adding an SNRI to → recognize serotonin syndrome risk
— Patient with FM requests oxycodone for flare → Best response: non-opioid multimodal plan; offer acetaminophen, reinforce exercise, schedule follow-up
— Elderly woman with FM on amitriptyline now confused and falling → Stop amitriptyline (Beers), switch to duloxetine
— 68-year-old with new diffuse shoulder/hip pain, morning stiffness, ESR 78 → PMR, start prednisone, evaluate for GCA — not FM
— Patient on simvastatin with new diffuse myalgia, mildly elevated CK → statin myopathy, discontinue statin
— FM-like picture with snoring, BMI 38, hypertension → screen for OSA, polysomnography
— RA patient with controlled inflammation but persistent diffuse pain and fatigue → concomitant fibromyalgia; add multimodal FM therapy, do not escalate biologics
— Pregnant FM patient with worsening pain → non-pharmacologic first; acetaminophen if needed; avoid NSAIDs after 20 weeks
— Patient discharged on pregabalin, oxycodone, alprazolam after surgery, with FM history → identify respiratory depression risk; deprescribe overlap; co-prescribe naloxone
— Patient asks if FM is a "real" diagnosis → Validate, explain central sensitization, set functional goals
— Patient on duloxetine 60 mg × 3 months, pain unchanged but back to work part-time, exercising 3×/week → Continue therapy; this is treatment success
Step 3 management: The right answer almost always emphasizes function over pain score, non-pharmacologic before pharmacologic, and avoid opioids/benzodiazepines.
Board pearl: If a stem asks for the single most effective intervention, choose aerobic exercise; if it asks for the best first medication, choose duloxetine (or amitriptyline for sleep-dominant phenotypes).
Fibromyalgia is a chronic central sensitization syndrome diagnosed clinically by widespread pain plus fatigue, unrefreshing sleep, and cognitive symptoms for ≥3 months, managed with a multimodal plan centered on patient education, graded aerobic exercise, and cognitive behavioral therapy, with duloxetine, pregabalin, milnacipran, or low-dose amitriptyline added when needed — while opioids, chronic NSAIDs, and benzodiazepines are avoided.
Board pearl: When in doubt on a Step 3 FM question — choose exercise, CBT, and an SNRI, validate the patient, and follow up in 2–4 weeks.